BREAKING Police to announce arrests in Toronto Pearson airport gold heist
Police say that arrests have been made in connection with a $20 million gold heist at Toronto Pearson International Airport one year ago.
An experimental Alzheimer's drug modestly slowed the brain disease's inevitable worsening -- but the anxiously awaited new data leaves unclear how much difference that might make in people's lives.
Japanese drugmaker Eisai and its U.S. partner Biogen had announced earlier this fall that the drug lecanemab appeared to work, a badly needed bright spot after repeated disappointments in the quest for better treatments of the incurable disease.
Late Tuesday, the companies provided full results of the study of nearly 1,800 people in early stages of the mind-robbing disease. The data was presented at an Alzheimer's meeting in San Francisco and published in The New England Journal of Medicine.
Lecanemab delayed patients' worsening by about five months over the course of the 18-month study, Eisai's Dr. Michael Irizarry told The Associated Press. Also, lecanemab recipients were 31 per cent less likely to advance to the next stage of the disease during the study.
"That translates to more time in earlier stages" when people function better, Irizarry said.
Every two weeks, study participants received intravenous lecanemab or a dummy infusion. Researchers tracked them using an 18-point scale that measures cognitive and functional ability.
The study's key finding: Those given lecanemab declined more slowly, a difference of not quite half a point on that scale over the 18 months, concluded the research team led by Dr. Christopher van Dyck at Yale University.
Doctors are divided over how much difference that may make for patients and families -- especially as the drug carries some worrying potential safety risks including brain swelling.
"It is unlikely that the small difference reported in this trial will be noticeable by individual patients," said Dr. Madhav Thambisetty of the National Institute on Aging, who noted he wasn't speaking for the government agency.
He said many researchers believe a meaningful improvement would require at least a difference of a full point on that 18-point scale.
But Dr. Ron Petersen, an Alzheimer's expert at the Mayo Clinic, said the drug's effect was "a modest one but I think it's clinically meaningful" -- because even a few months' delay in progression could give someone a little more time when they're functioning independently.
The trial is important because it shows a drug that attacks a sticky protein called amyloid -- considered one of several culprits behind Alzheimer's -- can delay disease progression, said Maria Carrillo, chief science officer for the Alzheimer's Association.
"We all understand that this is not a cure and we're all trying to really grasp what it means to slow Alzheimer's, because this is a first," Carrillo said.
But any delay in cognitive decline early on could be meaningful for "how much time we have with our loved ones in a stage of disease where we can still enjoy family and outings, vacations, bucket lists," she said.
Amyloid-targeting drugs can cause side effects that include swelling and bleeding in the brain, and lecanemab did as well. One type of this swelling was seen in about 13% of recipients. Eisai said most were mild or asymptomatic.
Also, two deaths have been publicly reported among lecanemab users who also were taking blood-thinning medications for other health problems. Eisai said Tuesday the deaths can't be attributed to the Alzheimer's drug.
But Mayo's Petersen said if lecanemab is approved for use in the U.S., he'd avoid prescribing it to people on blood thinners at least initially.
And Thambisetty said the death reports raise concern about how the drug may be tolerated outside of research studies "where patients are likely to be sicker and have multiple other medical conditions."
The Food and Drug Administration is considering approving lecanemab under its fast-track program, with a decision expected in early January. If approved, it would be the second anti-amyloid drug on the market.
Nearly all treatments available for the 6 million Americans with Alzheimer's -- and millions more worldwide with the most common form of dementia -- only temporarily ease symptoms. Scientists don't yet know exactly how Alzheimer's forms but one theory is that gunky amyloid buildup plays a key role, although drug after drug that targets it has failed.
In a contentious move last year, the FDA approved the first amyloid-targeting drug, Biogen's Aduhelm, despite lack of evidence of better patient outcomes. Insurers and many doctors have hesitated to prescribe the pricey drug -- another reason experts have anxiously awaited word of how well the newer lecanemab may work.
If the FDA approves lecanemab, patients and their families will need a voice in deciding whether it's worth the hassle of IV infusions and the risk of side effects for the chance of at least some delay in progression, Petersen said.
"I don't think we're going to stop the disease in its tracks" with just amyloid-targeting drugs, he added, saying it will take a combination of medications that target additional Alzheimer's culprits.
Researchers are preparing to test lecanemab with other experimental drugs, and how it works in high-risk people before they show the first signs of memory problems.
------------
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education. The AP is solely responsible for all content.
Police say that arrests have been made in connection with a $20 million gold heist at Toronto Pearson International Airport one year ago.
A group of doctors say Canadian cancer screening guidelines set by a national task force are out-of-date and putting people at risk because their cancers aren't detected early enough.
Lululemon says it is combining function and fashion in its first-ever summer kit for Canada's Olympians and Paralympians.
The strain placed on Canadian health care during the COVID-19 pandemic shows no sign of abating, and the top official of the Canadian Medical Association (CMA) is warning that improving the system will be a 'slow process' requiring sustained investment.
An Ontario woman says she never expected to be gifted a Blue Jays jersey for her ailing husband when she sat alone at the team’s home opener next to a couple of kind strangers.
After its last closure in 2021, it has now reopened for guided tours of the air raid shelter and the bunker. The complex now includes a multimedia exhibition about Rome during World War II, air raid systems for civilians, and the series of 51 Allied bombings that pummeled the city between July 1943 and May 1944.
Canadians will learn Tuesday the entirety of the federal Liberal government's new spending plans, and how they intend to pay for them, when Deputy Prime Minister and Finance Minister Chrystia Freeland tables the 2024 federal budget.
The family of a Victoria, B.C., woman who was seriously injured in an accident in Thailand is pleading for help as medical bills pile up.
An immersive experience inside a massive dome coined 'The Brain' is helping youth learn about brain function and addiction
Just steps from Parliament Hill is a barber shop that for the last 100 years has catered to everyone from prime ministers to tourists.
A high score on a Foo Fighters pinball machine has Edmonton player Dave Formenti on a high.
A compound used to treat sour gas that's been linked to fertility issues in cattle has been found throughout groundwater in the Prairies, according to a new study.
While many people choose to keep their medical appointments private, four longtime friends decided to undergo vasectomies as a group in B.C.'s Lower Mainland.
A popular highway in Alberta's Banff National Park now has a 'no stopping zone' to help protect two bears.
B.C. resident Robert Conrad spent thousands of hours on Crown land developing an unusual bond with deer.
A Sudbury woman said her husband was bringing the recycling out to the curb Wednesday night when he had to make a 'mad dash' inside after seeing a bear.
A school teacher who took part in the Quebec version of the Survivor reality TV show took time off work to be a contestant is now out of a job.
A young actor from Prince Edward Island is getting the chance to fulfill a childhood dream, playing the precocious and iconic Anne Shirley on stage.